Added to YB: 2024-10-03
Pitch date: 2024-10-02
RVNC [neutral]
Revance Therapeutics, Inc.
-1.15%
current return
Author Info
Special Situation Investments focuses on event-driven trades and low risk arbitrage opportunities with short term catalysts. Sign up for the newsletter.
Company Info
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally.
Market Cap
EUR 538.8M
Pitch Price
EUR 5.20
Price Target
N/A
Dividend
N/A
Sector
Pharmaceuticals
Category
special_situation
Revance (RVNC) Faces Uncertainty: Teoxane Conflict Raises Doubts About Crown Labs Merger
RVNC (merger arb): 28% merger spread due to Teoxane dispute (50% sales). Crown Labs likely mainly wants Daxxify (Botox competitor). Deal may close at lower price if Teoxane issue unresolved. Parties discussing remedies. Teoxane owns 6.3% of RVNC. Large downside if merger fails. More research needed on agreement breaches.
Read full article (2 min)